Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 7Gastrointestinal 4Tumor-Agnostic 2Head & Neck 2Gynecologic 2Genitourinary 2Sarcoma 1

Conditions

Urothelial Cancer 1Carcinoma, Renal Cell 1

Interventions

Magnetic Resonance Spectroscopy 106Specimen Handling 87pembrolizumab 81enzalutamide 64Nivolumab 62Gemcitabine 59Docetaxel 51Abiraterone Acetate 44apalutamide 43Radiosurgery 43Androgen Antagonists 43Prednisone 42darolutamide 40Cisplatin 38Biopsy 36Radiotherapy 34cabozantinib 32Carboplatin 30abiraterone 29Pluvicto 29Ipilimumab 29durvalumab 25Leuprolide 24enfortumab vedotin 23X-Rays 23Radiation 23olaparib 20atezolizumab 20Standard of Care 20avelumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Tiragolumab × Genitourinary × 90 days × Clear all
NCT05805501 2026-05-12

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Hoffmann-La Roche

Phase 2 Active not recruiting
199 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT05645692 2026-04-29

A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

Hoffmann-La Roche

Phase 2 Active not recruiting
204 enrolled
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡